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Abstract
Objective: The current study aimed to explore whether the subjective effects of microdosing
psychedelics are comparable to those of yoga in relation to psychological wellbeing,
depression, anxiety and stress. It also aimed to explore the relationship between yoga,
microdosing and personality variables including neuroticism, openness and absorption.
Method: The sample comprised 339 participants, yoga (n = 131), microdose (n = 69),
microdose and yoga (n = 54) and control (n = 85). All completed an online survey concerning
personality (M5-50 and Tellegen Absorption Scale), mood (Depression, Anxiety and Stress
Scale-21) and wellbeing (Ryff Scales of Psychological Wellbeing).
Results: The yoga and microdosing groups scored significantly higher on psychological
wellbeing and absorption than did control. The microdosing and yoga group had lower
depression scores than the microdose only group, and lower anxiety scores than the yoga only
group. Furthermore, the microdosing and yoga group had the highest absorption score.
Openness was significantly lower in the control group than in all other groups.
Conclusions: While we cannot infer that yoga and microdosing leads to increased wellbeing,
openness and absorption, or to decreased depression and anxiety,
the findings suggest that the subjective effects of microdosing psychedelics are comparable to
those of yoga and that the combination of both might be beneficial.
Key words: hallucinogen, microdose, openness, psychedelic, wellbeing, yoga.
Key points:
What is already known about this topic
•

Previous researchers have found yoga has improved psychological wellbeing,
decreased depressive and anxiety symptoms, decreased neuroticism, and
increased openness and absorption.

• A small number of recent studies have found that taking subthreshold doses of
psychedelic substances, known as microdosing, has improved psychological
wellbeing, reduced depressive, anxiety and stress symptoms and increased the
personality traits of openness and absorption.
• However, most research concerning psychedelics, wellbeing and personality
focuses on high doses of psychedelics. For example, 30 mg/70 kg of
psilocybin has significantly increased openness.
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What this topic adds
•

We are the first researchers to compare the effects of yoga with psychedelic
microdosing on wellbeing and personality.

•

Our findings suggest the effects of microdosing psychedelic substances might
be comparable to those of yoga.

•

Our study implies the combination of both yoga and microdosing have
complimentary effects on general wellbeing and absorption.
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A quantitative exploration of the relationships between regular yoga practice, microdosing
psychedelics, wellbeing and personality variables
Yoga incorporates physical and mental practices with the aim of achieving selfrealisation or union between body, mind and spirit (Ivtzan & Jegatheeswaran, 2015; Moliver,
Mika, Chartrand, Haussmann, & Khalsa, 2013). Yoga has been related to improved physical
and psychological health in a range of populations (Büssing, Khalsa, Michalsen, Sherman, &
Telles, 2012; Jeter, Slutsky, Singh, & Khalsa, 2015). For example, Moliver et al. (2013)
found that hours of yoga practice correlated with higher levels of psychological wellness.
Similarly, Ivtzan and Jegatheeswaran (2015) found that psychological wellbeing increased
with length of yoga practice. In a randomised controlled trial (RCT) by Hartfiel, Havenhand,
Khalsa, Clarke, and Krayer (2011), yoga was found to significantly improve wellbeing and
mood. Yoga has also been related to decreases in depressive and anxiety symptoms (Lin, Hu,
Chang, Lin, & Tsauo, 2011).
There is some evidence that microdosing also improves psychological wellbeing
(Fadiman, 2011). Microdosing involves taking 1/10 of a recreational dose of a psychedelic
drug such that there is no apparent alterations in consciousness or feelings of intoxication that
are generally associated with recreational doses of psychedelics (Fadiman, 2011). People
typically microdose every third day to avoid the tachyphylaxis associated with psychedelic
drugs, which reduces the drug’s efficacy. Classic psychedelic drugs, including psilocybin,
lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT) and mescaline, affect
serotonin (or 5-Hydroxytryptamine [5-HT]) pathways in the brain as 5HT2A receptor agonists
(Nichols, 2016).
Lea, Amada, Jungaberle, Schecke, and Klein (2020) found that most participants who
disclosed microdosing reported improved mood and anxiety on the days they microdosed.
Participants in a qualitative study of microdosing reported that the practice led to decreased
depressive and anxiety symptoms (Johnstad, 2018). Subsequently, Polito and Stevenson
(2019) examined 63 people who self-reported microdosing and found that depressive and
stress symptoms reduced after 6 weeks. Anderson et al. (2019) completed a cross-sectional
study comparing 315 non-microdosers with 594 self-reported microdosers. They found that
microdosers had lower scores on measures of dysfunctional attitudes and negative
emotionality. Individuals low in dysfunctional attitudes are less likely to be vulnerable to
stress (Jarrett et al., 2012) and depression (Adler, Strunk, & Fazio, 2015), while individuals
high in negative emotionality, including anxiety and depression, have an increased likelihood
of developing a mental health problem (Lahey, 2009).
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To our knowledge there have been two clinical trials of microdosing. Bershad,
Schepers, Bremmer, Lee, and de Wit (2019) randomly administered either a placebo, 6.5, 13,
or 26 µg of LSD to 20 healthy adults. They observed dose-respondent subjective changes,
including increased vigour. Vigour incorporates being cheerful, alert, active, lively, carefree
and energetic (Bershad et al., 2019). Yanakieva, Family, Williams, Luke, and Terhune (2019)
conducted a double-blind study in which 48 healthy older adults (Mage = 62.92, SD = 5.65)
were administered either a placebo, 5, 10, or 20 µg of LSD and completed a cognitive task
three hours after administration. While they found that participants administered LSD
performed better in a cognitive task compared to controls, there was a general trend towards
lower doses of LSD showing the greatest improvement in participants’ performance on the
task that was not statistically significant. This latter finding might have been due to low
statistical power related to sample size.
Personality has typically been conceptualised to comprise a set of traits that are
reasonably stable and consistent over time and across contexts with few interventions shown
to change an individual’s personality. However, both yoga and microdosing appear to lead to
changes in personality. When high doses of psilocybin (30 mg/70 kg) have been
administered, significant increases in openness have been observed that were sustained at a
16-month follow-up (MacLean, Johnson, & Griffiths, 2011). Openness is one of the Big Five
personality factors, which refers to broad-minded tolerance of others’ values and viewpoints,
aesthetic appreciation, sensitivity, imagination, and fantasy (MacLean et al., 2011). Polito
and Stevenson (2019) did not observe any change in openness among self-reported
microdosers and found increases in neuroticism, which is another of the Big Five personality
factors. Neuroticism comprises anxiety, hostility, depression, self-consciousness,
impulsiveness and vulnerability (Yadav, Magan, Mehta, Mehta, & Mahapatra, 2012).
Anderson et al. (2019) found that open-mindedness was higher among people who
microdosed compared to controls.
In contrast, yoga practice has been consistently related with increased openness and
decreased neuroticism. For example, research examining the effectiveness of yoga among 90
hospital outpatients with chronic disease found that following the 10-day yoga retreat, they
had higher levels of openness, and lower levels of neuroticism, than at baseline (Yadav et al.,
2012). This change in personality was not seen in the control condition. A two-year followup of one participant from Yadav et al’s study who had been diagnosed with chronic fatigue
syndrome showed he had experienced a marked improvement in symptoms, and that the
changes in openness and neuroticism were maintained (Yadav, Sarvottam, Magan, & Yadav,
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2015). A cross-sectional study by Misra, Gupta, Alreja, and Prakash (2013) found people
who had practised yoga for 10 years or longer (n = 26) had significantly lower levels of
neuroticism compared with yoga practitioners who had less than two years (n = 38) of
practice.
Both microdosing and yoga practice have been associated with increased levels of
absorption. Absorption influences how easy it is to enter altered states of consciousness
(Menzies, Taylor, & Bourguignon, 2008). For example, Polito and Stevenson (2019) found
self-reported absorption significantly increased after a microdosing period of six weeks.
However, the relationship between absorption and yoga appears to be reciprocal, with
absorption also predicting the degree to which people are able to engage in meditation during
yoga. For example, Hölzel and Ott (2006) found that people who had practised meditation for
a longer time were more absorptive and that absorption influenced meditation depth more
than the amount of meditation practice.
The current study aimed to contribute to the growing body of knowledge about
microdosing by exploring whether the relationship between microdosing and wellbeing is
similar to that of regular yoga practice and wellbeing. It also aimed to enhance our
understanding of the relationships between microdosing and personality and to explore
whether these relationships are comparable to those associated with yoga. We explored
whether or not there were differences in wellbeing, depression, anxiety and stress between
people who microdose, practise yoga or do neither. Additionally, we explored whether there
were differences in openness, neuroticism and absorption between people who microdose,
practise yoga, or do neither. These psychological dimensions were selected since there is
evidence that engaging in yoga and microdosing can affect these variables. As such, it was
hypothesised that people who engage in yoga or microdosing would have increased levels of
wellbeing, openness and absorption compared to the control group. However, since this is the
first study to our knowledge to compare microdosing with yoga, there was no hypothesis
regarding differences between these groups.
Method
Research design
The current study employed a quasi-experimental survey design, which was
conducted online via Qualtrics between June and August 2018. The independent variable was
activity, with three planned conditions: microdosing, yoga, or neither (control). However,
during the recruitment process we identified participants who reported engaging in both
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microdosing and yoga (MY), so this was included as a fourth condition. The dependent
variables included measures of wellbeing, mood and personality. Specifically, Ryff Scales of
Psychological Wellbeing was used to measure wellbeing, the Depression, Anxiety and Stress
Scale-21 (DASS-21) was used to measure mood, and the M5-50 and the Tellegen Absorption
Scale were used as personality measures. The survey was piloted with six people known to
the researchers to assess face validity, formatting, clarity and duration of the task.
Participants
Yoga and microdosing participants were recruited via advertisements distributed on
websites, social media and mailing lists of organisations dedicated to psychedelics or yoga.
Organisations included Psychedelic Research in Science and Medicine, Entheogenesis
Australis, the Australian Psychedelic Society, Kundalini Yoga Western Australia, Yoga
Australia and yoga schools across Australia. The control participants were recruited via Turk
Prime Panels, an international crowdsourcing platform. Participants were excluded if they
were under 18 years of age, had a current diagnosed mental disorder, a history of psychosis
and/or a current substance use disorder.
Materials
Ryff Scales of Psychological Wellbeing
Ryff Scales of Psychological Wellbeing was used as a measure of wellbeing. It
consists of six subscales with seven items in each. These include autonomy, environmental
mastery, personal growth, positive relations with others, purpose in life and self-acceptance.
Factor analytic studies provide support for the six-factor structure (for review, see Ryff &
Singer, 2008). Participants respond using a 6-point (1-6) Likert type scale ranging from
Strongly Disagree to Strongly Agree. Internal consistencies have been reported as ranging
from α = .69 to α = .85 (Morozink, Friedman, Coe, & Ryff, 2010). Test re-test reliability has
ranged from .78 - .97 (Akin, 2008). Environmental mastery was not administered due to an
error, which means the data were not captured.
The Depression, Anxiety and Stress Scale-21 (DASS-21)
The DASS-21 measures depression, anxiety and stress (Antony, Bieling, Cox, Enns,
& Swinson, 1998). Participants are asked to rate how much different statements applied to
them during the past week using a 4-point (0-3) Likert scale ranging from 0 = Did not apply
to me at all to 3 = Applied to me very much or most of the time. There is evidence that the
DASS-21 has convergent validity with a correlation of .81 found between the depression
subscale of the DASS-21 and the Beck Depression Inventory and a correlation of .74 between
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the DASS-21 and the Beck Anxiety Inventory (Lovibond & Lovibond, 1995). The scale is
widely used and has reported internal consistencies of depression (α = .94), anxiety (α = .87)
and stress (α = .91; Antony et al., 1998).
M5-50
Openness and neuroticism were measured using these two subscales of the M5-50
(Socha, Cooper, & McCord, 2010). Participants are asked to rate their level of agreement
with 20 statements on a 5-point (1-5) Likert type scale (1 = Inaccurate to 5 = Accurate). The
M5-50 subscales of openness and neuroticism have good internal consistency with α = .78
and α = .86 respectively (Socha et al., 2010). The M5-50’s construct validity has also been
supported through the confirmatory factor analysis with the proposed five factor providing
the best fit (Socha et al., 2010). Warlick, Ingram, Vuyk, and Multon (2019) demonstrated
convergent validity of the M5-50 through moderate to strong correlations between the M5-50
neuroticism subscale and the neuroticism domains of the NEO-Personality Inventory-3 (α =
.61 - .89).
Tellegen Absorption Scale
The Tellegen Absorption Scale was used to measure the personality trait of
absorption. Participants are asked to state whether 34 statements were true or false for them.
The scale’s construct validity was developed following a series of factor-analytic
examinations that revealed a six-factor structure that form one higher-order factor (Tellegen
& Atkinson, 1974) that has excellent internal consistency, with α reported to range between
.92 - .95 (Hölzel & Ott, 2006; Studerus, Gamma, Kometer, & Vollenweider, 2012).
Procedure
Following the receipt of ethics approval from the university [insert HREC reference
number in final copy], potential participants were directed to a Qualtrics page containing
information about the study. Rather than recording re-identifiable informed consent,
participants had to check a box to indicate that they had read and understood this information
before proceeding to the online survey, so they were able to remain anonymous since the
research involved questions about illicit behaviour. Participants were first asked to respond to
three separate items to confirm they met the inclusion criteria of being over 17 years of age
and not having a current diagnosed mental disorder or a history of psychosis. The Alcohol,
Smoking and Substance Involvement Screening Test (ASSIST) was then completed by
participants to identify people with a current substance use disorder. Developed for the World
Health Organization (WHO; World Health Organization, 2010), the ASSIST has been subject
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to stringent testing ensuring its reliability and validity. In accordance with the
recommendations by the WHO, people who scored 27 or above for any of the eight drugs for
which the ASSIST assesses were excluded from the study and provided with information
about support services. Following basic demographic questions, and items concerning
respondents’ history of yoga and microdosing behaviour, all participants completed the
aforementioned psychometric measures of wellbeing, mood, personality and drug use.
Analysis
The data from Qualtrics were exported to SPSS where they were screened to ensure
that the assumptions for univariate and multivariate parametric analysis were met. Unless
stated otherwise, all assumptions were met. To explore whether there were differences in
psychological wellbeing between participants who microdosed, practised yoga or did neither,
a Multivariate Analysis of Variance (MANOVA) was planned using Ryff Scales of
Psychological Wellbeing as the dependent variables (DVs). A MANOVA using the three
DASS-21 subscales as DVs was also planned. Separate Analysis of Variance (ANOVAs)
were then conducted to explore whether there were differences in personality using the two
M5-50 subscales and the Tellegen Absorption Scale. Alpha was set at .05 with Bonferroni
adjustments for post-hoc analyses to reduce the likelihood of Type I error.
Results
From a total of 488 recorded responses, 59 people were excluded from participating
in the study because their ASSIST scores indicated their substance use was harmful
according to the World Health Organisation scoring criteria. Seventy-two participants did not
complete all the measures. No imputation methods were performance and these cases were
excluded from the analyses. An additional 18 cases were excluded due to being identified as
multivariate outliers according to Mahalanobis and Cooks distance criteria described by
Tabachnick and Fidell (2007). The final sample comprised 339 participants. Respondents’
demographic characteristics are presented in Table 1.
(INSERT TABLE 1 HERE)
Pearson’s Chi-square Tests of Independence indicated there were significant
differences between the groups in the pattern of responses across gender χ² (3, 324) =
101.282, p = < .001, education, χ² (6, 324) = 45.87, p = < .001, and employment χ² (9, 320) =
77.634, p = < .001. Significant standardised residuals indicated people who reported
engaging in yoga were more likely to be female, have a higher level of education and be self-
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employed. A one-way analysis of variance (ANOVA) revealed a statistically significant main
effect for age using Welch’s F since Homogeneity of variance was not met, F (3,300) =
19.720, p = < .001. Games-Howell post-hoc analysis revealed the mean age of the yoga and
control participants was significantly higher p = <.001 than either the MY or the microdose
participants.
Over half (50.6%) of the microdose participants reported they had been microdosing
for 6 months or less, and 8.9% reported that they had been microdosing for two years or
longer. Microdose participants reported a high level of uncertainty regarding dose. Almost
half (48.1%) reported always carefully weighing dose, 29% reported eyeballing the dose,
19.1% reported sometimes measuring their dose and 3.8% didn’t know what a microdose
was. Many microdose participants (24.1%) microdosed every third day. See Table 2 for
microdose substances reported by the participants.
(INSERT TABLE 2 HERE)

Yoga participants were mostly long-term practitioners with 10.7% having practised
for two years, 9.8% having practised for 5-10 years and 35.9% for longer than 10 years.
Almost a third (32.8%) of yoga participants practised daily, 22.1% practised 5 times per
week, 17.6% practised 3 times per week and 4.6% practised weekly. All yoga participants
practised meditation. Mantra (chanting, repeating phrase silently or aloud) was included in
the practice of 50.4% yoga participants, 87.8% of yoga participants practised pranayama
(breath control) and 70.2% practised drishti (specific point of focus). We were unable to
extract information about the length of yoga practice for the MY group.
A MANOVA was performed using Ryff Scales of Psychological Wellbeing F(15,
999) = 7.989, p = <.001, partial ɳ² = .107. While Box’s M was significant, indicating the
variance-covariance matrices were not homogeneous, Tabachnick and Fidell (2007) state that
MANOVA is robust against violations of this assumption. Subsequent ANOVAs showed
there were significant differences for personal growth F(3, 335) = 23.77, p = <.001, ɳ² = .176
and self-acceptance F(3, 335) = 8.780, p = <.001, ɳ² = .73. Pairwise comparisons using the
Games-Howell procedure showed that the control group had significantly lower scores for
the psychological wellbeing component of personal growth than the yoga group p = <.001, d
= .76, the microdose group p = .001, d = .62 and the MY group p = <.001, d = .75. Selfacceptance scores were significantly higher for the yoga group than the microdose group p =
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.001, d = .43 and the control group p = .001, d = .44. Figure 1 shows mean subscale scores
for each condition.
(INSERT FIGURE 1 HERE)
The control group had significantly lower overall psychological wellbeing scores than
the yoga group p = <.001, d = .57 and the MY group p = .001, d = .42. The microdose group
(M = 30.76, SD = 4.4) also scored higher in psychological wellbeing than the control (M =
29.39, SD = 3.9). See Table 3 for the mean scores for total psychological wellbeing by
condition.
(INSERT TABLE 3 HERE)
To explore whether there were group differences in depression, anxiety or stress, a
second MANOVA was conducted using the DASS-21, F(9, 1011) = 13.98, p < .001, partial
ɳ² = .11. Box’s M was significant, indicating the assumption of homogeneity of variancecovariance matrices was violated. Post-hoc ANOVAs showed there were significant
differences for depression F(3, 335) = 11.47, p < .001, partial ɳ² = .097; anxiety F(3, 335) =
9.18, p <.001, partial ɳ²= .076 and stress F(3, 335) = 5.74, p < .001, partial ɳ² = .049.
Pairwise comparisons using the Games-Howell procedure showed that the yoga group scored
significantly higher in anxiety than the microdose group p <.001, d = .53 and the control
group p = .001, d = .42. However, the yoga group scored significantly lower in stress than the
microdose group p <.001, d = .58 and the MY group p = .005, d = .38. The microdose group
scored significantly higher in depression than the yoga group, p = .002, d = .40. See Table 3
for descriptive statistics.
An ANOVA was performed using the M5-50 as the DV to assess whether there were
group differences in openness. A statistically significant main effect was revealed for
openness, F(3, 335) = 23.165, p = < .001. The effect size ɳ² = .17 was considered large, as
outlined by Cohen (1988). Tukey’s post-hoc procedure (using an a priori alpha of .05)
revealed the control group was significantly lower in mean openness scores compared to the
microdose group (p = <.001), the yoga group (p = <.001) and the MY group (p = <.001).
Effect sizes for the three comparisons were d = 0.81, 0.73 and 0.64 respectively.
An additional ANOVA was conducted to assess whether there were group differences
in neuroticism. The main effect for neuroticism was not significant F(3, 335) = 1.99, p =
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.115. Table 3 shows the mean scores and standard deviations for openness and neuroticism
across the four conditions.
Finally, to explore whether there were statistically significant differences concerning
absorption between the microdose group, yoga group, MY group and control, an ANOVA
was conducted. A statistically significant main effect was revealed, Welch’s F(3, 335) =
10.45, p = < .001, effect size ɳ² = 0.11. As the assumption of homogeneity of variance was
not met, the Games-Howell procedure was used for post-hoc analyses. The results showed
that the control group had significantly lower absorption scores than the microdose group p =
<.001, the yoga group p = <.001 and the MY group p = <.001. Effect sizes for the
comparisons were d = 0.43, 0.57 and 0.53 respectively. Table 3 shows the total Tellegen
Absorption Scale scores and standard deviations across the four groups.
Discussion
In the present, exploratory study we aimed to investigate differences in mood and
wellbeing between samples of people who either microdose, practise yoga, or engage in
neither. We also aimed to investigate the personality traits of openness, neuroticism and
absorption among those who microdose compared to those who practise yoga or do neither
However, during the analysis process, a fourth group was identified who engaged in both
yoga and microdosing (MY).
The yoga group reported better overall wellbeing compared to the control. In
particular, the yoga group scored significantly higher in two of the four measured
components of wellbeing, personal growth and self-acceptance, than the control group. This
was consistent with the results of previous researchers who found that yoga significantly
improved wellbeing (Hartfiel et al., 2011), that wellbeing was significantly related to length
of yoga practice (Ivtzan & Jegatheeswaran, 2015) and that psychological wellness was
significantly related to hours practising yoga (Moliver et al., 2013). The microdose group
scored significantly higher than the control group in one of the four measured components of
wellbeing, personal growth. To our knowledge, we were among the first researchers to
generate empirical evidence that suggests microdosing might improve wellbeing. A study
published after this manuscript was submitted for publication found that most participants
who disclosed microdosing reported improved mood and anxiety on the days they
microdosed (Lea et al., 2020).
However, the yoga group reported more symptoms of anxiety than the control, and
the microdose group reported more symptoms of depression than the control. As our study
was cross-sectional, it is possible that the relatively high anxiety among participants who
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engaged in yoga and relatively high depression among participants who microdosed was due
to sampling issues. This might be why our findings were not consistent with the findings of
previous researchers who found that yoga reduced anxiety and depression (Khalsa, Shorter,
Cope, Wyshak, & Sklar, 2009; Lin et al., 2011), and that self-reported microdosing decreased
depressive symptoms (Polito & Stevenson, 2019).
Since previous researchers found that open-mindedness was higher among people
who microdosed than people who did not (Anderson et al., 2019) and that yoga was
significantly related to increased openness (Yadav et al., 2012; Yadav et al., 2015), to achieve
our second aim, we sought to find out whether there were differences in openness between
people who microdose, practise yoga or do neither. Consistent with previous findings,
openness was significantly higher in the microdose group than the control group. Openness
was also significantly higher in the yoga group than the control, and in the combined yoga
and microdosing group (MY) than the control. Since past researchers have found that selfreported microdosing led to increased neuroticism at follow up (Polito & Stevenson, 2019),
and that a yoga intervention significantly decreased neuroticism compared to a control group
(Yadav et al., 2012), we sought to find out whether there were differences in neuroticism
between people who microdose, practise yoga or do neither. However, we did not observe
any statistically significant differences between the groups. Finally, consistent with previous
research (Polito & Stevenson, 2019; Simpkins & Simpkins, 2010), the yoga and microdosing
groups scored significantly higher in absorption than the control group.
The combination of microdosing and yoga (MY) appeared to have a complimentary
effect. The microdosing and yoga group had lower depression scores than the microdose only
group, and lower anxiety scores than yoga only group. Furthermore, the microdosing and
yoga group had the highest absorption score. Consistent with our findings, psilocybin
combined with meditation increased psychological wellbeing more than psilocybin alone
(Griffiths et al., 2018). This resonates with the concept of set and setting in psychedelicassisted psychotherapy (Hartogsohn, 2016). The context of microdosing might contribute
significantly to microdosing effects.
Our cross-sectional design presents some limitations. While, our exploratory study
found significant relationships between yoga, microdosing, wellbeing, openness and
absorption, we cannot infer that yoga and microdosing leads to increased wellbeing, openness
and absorption. Similarly, we cannot conclude that the combination of yoga and microdosing
leads to decreased depression or lower anxiety. In addition, we found significant differences
in age, gender, employment and education between the conditions, which could have
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confounded our findings. Bias could also have impacted our results due to the use of selfreported measures.
It was impossible to know the precise dosages taken and whether all reported
psychedelics consumed were psychedelics. This is because participants were using
substances in an illegal context where the substances were unregulated. For example, less
than half of microdose participants reported always carefully weighing their dose. In contrast,
the substances and dosages used in published RCTs are known and consistent for all
participants in each condition.
Participants who scored high on the ASSIST were excluded from the study. While
these people were potentially vulnerable, they also potentially had more to gain in terms of
improved wellbeing. It has also been suggested that psychedelics are means of treating
substance use disorders (Bogenschutz et al., 2015). However, the relationship between people
with substance use disorders and microdosing is an important, if ethically complex area of
research, that was beyond the scope of our study.
Our study implies that both yoga and microdosing may be effective strategies for
improving wellbeing. While microdosing was associated with significantly higher levels of
one component of wellbeing (personal growth), yoga practitioners scored significantly higher
in overall wellbeing and two specific components (personal growth and self-acceptance)
compared to the control. Yoga and microdosing also appeared to have a strong relationship
with levels of absorption. Yoga and microdosing participants both scored higher in
absorption than the control. Participants that combined microdosing and yoga scored higher
in absorption than the control and individual and yoga microdosing groups. Yoga,
microdosing and their combination may be useful for improving emotional responsiveness
(Tellegen, 1981) and the efficacy of mind-body interventions (Menzies et al., 2008), such as
mindfulness (Hölzel & Ott, 2006), which have been shown to be significantly influenced by
absorption.
Future research could explore reasons for the inconsistencies between the findings of
the current study and previous research concerning the influence of yoga and microdosing on
anxiety, depression and neuroticism. It will also be important to explain why microdosing
was significantly related to some aspects of wellbeing and not others. A longitudinal study or
RCT could help address this, and some of the aforementioned limitations of our crosssectional design.
Future research could also investigate other psychological constructs impacted on by
microdosing or yoga, such as attention, mindfulness and sense of agency, and the influence of
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combined microdosing and yoga on these constructs. Additional interventions that may
improve the efficacy of combined yoga and microdosing should be considered.
In conclusion, participants engaged in yoga and microdosing were found to have
higher mean wellbeing scores compared to controls. Mean openness and absorption scores
were significantly higher among the yoga and microdose participants. A novel finding was
the complimentary effect of microdosing and yoga concerning depression, anxiety and
absorption. It is hoped that the results of this study will form the basis for more rigorous
research under controlled conditions.
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Table 1. Demographic Characteristics.
Microdose

Yoga

Control

MY

34.37 (10.79)

44.85 (12.25)

47.8 (17.40)

33.35 (9.70)

Male

51 (73.9)

17 (12.3)

40 (45.4)

33 (61.1)

Female

17 (24.6)

121 (87.6)

44 (50)

20 (37)

Other

1 (1.40)

__

__

1 (1.9)

High school

31 (44.9)

12 (9.1)

31 (36.4)

16 (29.6)

Further

12 (17.3)

33 (25.1)

29 (34.1)

14 (25.9)

26 (37.6)

84 (64.1)

22 (16.7)

21 (38.8)

4 (5.7)

2 (1.5)

3 (3.5)

3 (5.6)

Fulltime

25 (36.2)

29 (22.1)

26 (30.5)

23 (42.5)

Part time

22 (31.9)

36 (27.4)

13 (15.2)

8 (14.8)

5 (7.2)

17 (12.9)

40 (47)

5 (9.2)

16 (23.2)

48 (36.6)

4 (4.7)

18 (33.3)

Mean Age (SD)
Gender (%)

Highest level of
education (%)

education
Tertiary
Other
Employment
status (%)

Unemployed
Self-employed

Note: Missing data for employment = microdose 1, yoga 1, control 2. Missing data for age =
yoga 15, microdose 1. Control 1 and MY 3. SD = standard deviation.
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Table 2. Microdose Substances Reported by Microdose and MY Participants.
Microdose

MY

Total

Psilocybin

44

32

76

LSD

43

32

75

DMT

4

9

13

Mescaline

1

1

2

251-NBome (2c-1-NBome)

1

0

1

2C-B

0

2

2

Mescaline NBome

1

0

1

1P-LSD

3

5

8

4 – Acetoxy DMT

1

0

1
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Table 3. Descriptive Statistics for Psychological Wellbeing, Depression, Anxiety, Stress,
Neuroticism, Openness and Absorption.
Variable

N

Mean

SD

Lower

Upper

(CI, 95%)

(CI, 95%)

Psychological

Control

85

29.39

3.9

28.55

30.24

Wellbeing

Microdose

69

30.76

4.4

29.70

31.81

Yoga

131

32.33**

3.9

31.64

33.02

MY

54

32.15**

4.2

31.07

33.21

Control

85

2.41

2.97

1.87

3.39

Microdose

69

3.95*

3.54

3.03

4.70

Yoga

131

2.15

2.44

1.73

2.60

MY

54

2.62

2.87

1.87

3.39

Control

85

2.16

2.54

1.61

2.71

Microdose

69

2.00

1.80

1.57

2.43

Yoga

131

3.60**

2.83

3.11

4.09

MY

54

2.52

2.02

1.97

3.07

Control

85

3.13

2.95

2.50

3.80

Microdose

69

4.48

3.27

3.70

5.26

Yoga

131

2.18**

1.95

1.84

2.52

MY

54

3.96

3.34

2.96

4.80

Control

85

3.64

.502

3.54

3.75

Microdose

69

4.21**

.433

4.10

4.31

Yoga

131

4.08**

.491

4.00

4.17

MY

54

4.13**

.425

4.01

4.24

Control

85

2.28

.756

2.11

2.44

Microdose

69

2.44

.803

2.25

2.63

Yoga

131

2.17

.709

2.05

2.29

MY

54

2.22

.710

2.04

2.42

Control

85

15.40

9.30

13.40

17.40

Microdose

69

20.58**

7.03

18.90

22.27

Yoga

131

21.53**

6.72

20.36

22.69

MY

54

22.18**

7.17

20.23

24.14

Depression

Anxiety

Stress

Openness

Neuroticism

Absorption

Note: SD = standard deviation, CI = confidence intervals, * p <. 005 and ** p < .001.
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Figure 1
Mean Ryff Scales of Psychological Wellbeing Subscale Scores by Condition
40

*

*
Mean

30

20
Microdose
Yoga

10

MY
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0
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Note: Error bars represent 95% confidence intervals and * p <.001.

